Rodrigo Carrasco

Cardiologist, Cardio-oncologist, MD PhD, Scientist

[Rodrigo Carrasco @rcarrascoloza]

@RiveraTheurel @dineshpmcc1 @husam247 @Coleenten @drchrisyu @InbarNardi @PMunkCardiacCtr @UHN @CCardiacON The best team!👏👏👏

[Rodrigo Carrasco @rcarrascoloza]

@dramcarrillo9 @SIAC_cardio @husam247 @RiveraTheurel @oscaar84 👏👏👏

[Rodrigo Carrasco @rcarrascoloza]

@DrDiegoDelgado @PMCC @CongresoSIAC @SIAC_cardio 👏👏👏👏👏

[Rodrigo Carrasco @rcarrascoloza]

@RiveraTheurel @SCC_CCS @SIAC_cardio @dineshpmcc1 @husam247 @PMunkCardiacCtr @adribaran @oscaar84 @dramcarrillo9 The Dream Team!!!👏👏👏

[Rodrigo Carrasco @rcarrascoloza]

@husam247 @uoftmedicine @WCHospital @PMunkCardiacCtr 👏👏👏

[Fernando Rivera @RiveraTheurel]

Cardiac Rehab can be an important therapeutic tool in ATTR-CM 👇🏼@DrDiegoDelgado, #amyloidosis #cardiacamyloidosis #cardiacrehab

[dineshpmcc @dineshpmcc1]

Tremendous work by @drchrisyu @Coleenten to bring this pilot data together. This data along with feedback from the international #cardioonc community helped us design the ongoing RCT NCT061883437. Grateful for support of many colleagues & @CIHR_IRSC @ICOSociety @PMunkCardiacCtr

[Chris Y @drchrisyu]

Our #cardioonc pilot data in @JACCJournals (https://t.co/i4aZ2m0rrp) shows it may potentially be safe to stop #HeartFailure meds in pts with asymptomatic mild #cardiotoxicity & now improved #LVEF. Now time for the #RCT data! @dineshpmcc1 @husam247 @kaznegishi @dr_manisty @bmdwsg

[Chris Y @drchrisyu]

Our recent #cardioonc work (https://t.co/QwAckynYoa) showed baseline LA strain is not predictive of #cardiotoxicity in the #SUCCOUR trial. Although disappointing, it motivates us to find the elusive imaging biomarker for predicting CTRCD @kaznegishi @BeardedHeartDoc @dineshpmcc1

[Husam Abdel-Qadir @husam247]

Dear #cardiooncology colleagues,
We are planning a RCT to test less frequent cardiac imaging during HER2 targeted therapy for #breastcancer. We want your input re study design. It will be of great value.
Pls consider completing a 5-min questionnaire at https://t.co/q81wrmFomE

[Ana Barac, MD, PhD, FACC, FAHA @AnaBaracCardio]

Key lessions by phenomenal @dineshpmcc1 on gaps #whyCMR in #CardioOnc 1. Learn from positive and negative studies, 2. ask difficult questions, 3. improve risk stratification to improve outcomes #CMR2024
@ICOSociety @SCMRorg @TeresaLpezFdez1 @CardioOnc_MR_CT

[dineshpmcc @dineshpmcc1]

2/2 #cardioonc needs RCTs - observational studies remain essential to generate hypothesis and fuel RCTs!!

[dineshpmcc @dineshpmcc1]

1/2 Thanks Ron! I think you summarized our work perfectly "good rationale for RCT" – exactly as our conclusion. Given observational study, we used best poss methods (propensity matching, controls receiving a non-SGLT2 medication) to reduce confounding - impossible to eliminate.

[JACC Journals @JACCJournals]

#SGLT2 inhibitors do it again? Data from Drs. @husam247, @dineshpmcc1, et al suggest SGLT2is may reduce the rate of #HeartFailure hospitalization after #anthracycline-containing #chemotherapy. https://t.co/Y9r3fC2Tju

#JACCCardioOnc #CardioOnc #SGLT2i #CVD #CardioTwitter

[JACC Journals @JACCJournals]

Do #SGLT2i have a role in #CardioOnc?

Dr. @husam247 and team show that they may reduce the rate of #heartfailure hospitalization in patients treated with anthracycline containing #chemotherapy but not incident HF, #CVD or mortality. https://t.co/Y9r3fC2Tju #JACCCardioOnc

[Rodrigo Carrasco @rcarrascoloza]

@husam247 @dineshpmcc1 @Stats_research @IlianaLega @Padma_Kaul @TomasNeilan @trogersresearch @HeartandStroke @WCHospital Congratulations @husam247 !!

[Husam Abdel-Qadir @husam247]

This was a challenging study and I am grateful for the support of @dineshpmcc1 @Stats_research @IlianaLega @Padma_Kaul @rcarrascoloza @TomasNeilan. Much thanks to the study funder @trogersresearch, as well as @HeartandStroke and @WCHospital who fund my salary as a researcher!

[Husam Abdel-Qadir @husam247]

Caveat emptor! These are observational data and patients were quite different, so should NOT start using SGLT2I' without current indications. Pls read the important limitations of this analysis.

[Husam Abdel-Qadir @husam247]

There were no safety signals. HR for death trended towards benefit (HR 0.63; 95% CI 0.36-1.11). Diabetes compl'ns, incl ketoacidosis, were rare. This is an underestimate of what to expect in RCTs as patients were stabilized on SGLT2I & admin data are less sensitive for these dx.

[Husam Abdel-Qadir @husam247]

There were no hospitalizations for HF in the SGLT2i group (HR zero!). The HR any HF diagnosis indicated possible benefit (HR 0.55) but confidence intervals crossed one so the difference was not statistically significant.